Funding for this research was provided by:
Klinikum rechts der Isar der Technischen Universität München
Received: 23 April 2021
Accepted: 30 June 2021
First Online: 9 July 2021
: Dr. Spinner received consultancy fees, speaker’s honoraria, and/or reimbursement of travel expenses from Gilead Sciences, Eli Lilly, Janssen-Cilag, MSD and received consultancy fees from Molecular Partners and Formycon in the context of COVID-19. He also received research support indirectly from Apeiron, Eli Lilly, Gilead Sciences, and Janssen-Cilag. Outside this context, he received consultancy fees, speaker’s honoraria, and reimbursement of travel expenses from AbbVie, Gilead Sciences, Janssen-Cilag, MSD, and ViiV Healthcare/GSK, as well as research support (indirectly to his employer) from Gilead Sciences, GSK, Jansen-Cilag, MSD, and ViiV Healthcare. All other authors report no relevant conflict of interest.
: This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The local Ethics Committee of Technical University of Munich approved this study (No. 259/21 S).